Skip to content

Prof. Tony Mok, BBS

80
Prof. Tony Mok, BBS
莫樹錦教授
Share
qualifications
BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO
rank
Chairman
Li Shu Fan Professor of Clinical Oncology
orcid
0000-0002-8251-0551
email
tony@clo.cuhk.edu.hk

Specific Research / Sites of Interest

Lung cancer

  • Molecular targeted therapy on epidermal growth factor receptor (EGFR)

  • Development of biomarker for personalized medicine in lung cancer

  • Mechanism for and management of resistance to EGFR tyrosine kinase inhibitor

  • Development of novel targeted therapy (ELM-4 ALK, c-MET, IGF-1R)

  • Tumor vaccine against lung cancer (MAGE A3, MUC-1)

  • Immunotherapy

  • Plasma-based cfDNA for molecular diagnosis


 

Short Biography

Professor Tony S. K. Mok was trained at the University of Alberta, Canada and he subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Canada. After working as a community oncologist in Toronto, Canada for seven years, he returned to Hong Kong in 1996 to pursue an academic career.

Professor Mok is the Li Shu Fan Medical Foundation endowed Professor and Chairman of Department of Clinical Oncology at the Chinese University of Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. Professor Mok was the Principal Investigator and first author on the landmark IRESSA® Pan-Asia Study (IPASS), which was the first study that confirmed the application of precision medicine for advanced lung cancer. He has also led and co-led multiple studies including the FASTACT 2, IMPRESS, ARCHER 1050, ALEX and AURA 3. These projects address various aspects on management of EGFR mutation positive lung cancer, and basically have defined the current practice. He dedicates his work on precision medicine for lung cancer by also engaging in clinical research on ALK positive lung cancer and immunotherapy. The series of clinical trials, led or co-led by Professor Mok, have defined precision medicine for lung cancer. His work has been adopted by multiple international guidelines including NCCN, AMP/IASLC/CAP, ASCO and ESMO. He also contributes to the development of clinical research infra-structure in China and Asia. He cofounded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group and Asia Thoracic Oncology Research Group.

Professor Mok has contributed to over 220 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is an Associate Editor for thoracic oncology for the Journal of Clinical Oncology and other international journals. He is the Past President and Current Treasurer of the International Association for the Study of Lung Cancer (IASLC). He is active in international education activity and has made significant contribution to AACR, ASCO, CSCO and ESMO. His work was recognized by numerous awards including Bonnie Addario Award in 2015, Fellowship of the American Society of Clinical Oncology (FASCO) in 2017 and Paul Bunn Jr Scientific Award in 2017.

Most Representative Publications

1. Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, Soria JC. Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. J Clin Oncol. 2017 Oct 2. [Epub ahead of print]
2. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Aug 31;377(9):829-838.
3. Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Mocci S, Phan S, Shames DS, Smith D, Yu W, Paton VE, Mok T. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. J Clin Oncol. 2017 Feb;35(4):412-420.
4. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WSME, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer. N Engl J Med 2017 Feb; 376(7):629-640
5. Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K, Wu YL, Mekhail T, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS. Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-Positive non-small-cell lung cancer: Results from PROFILE 1014. J Clin Oncol. 2016 Aug 20;34(24):2858-65.
6. Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015 Aug;16(8):990-8.
7. BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, F Cappuzzo, J Paolini, T Usari, S Iyer, A Reisman, KD Wilner, J Tursi, F Blackhall; PROFILE 1014 Investigators. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. N Engl J Med. 2014 Dec 4;371(23):2167-77. (co-first author)
8. YL Wu, JS Lee, S Thongprasert, CJ Yu, L Zhang, G Ladrera, V Srimuninnimit, V Sriuranpong, J Sandoval-Tan, Y Zhu, M Liao, C Zhou, H Pan, V Lee, YM Chen, Y Sun, B Margono, F Fuerte, GC Chang, K Seetalarom, J Wang, A Cheng, E Syahruddin, X Qian, J Ho, J Kurnianda, HE Liu, K Jin, M Truman, I Bara, T Mok. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013 Jul;14(8):777-86.
9. M Fukuoka, YL Wu, S Thongprasert, S Sunpaweravong, SS Leong, S Sriuranpong, TY Chao, K Nakagawa, DT Chu, N Saijo, E Duffield, Y Rukazenkov, Y Speake, H Jiang, AA Armour, KF To, JCH Yang, TS Mok. Biomarker Analyses and Final Overall Survival Results from a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients with Advanced Non-Small-Cell Lung Cancer in Asia (IPASS). J of Clin Oncol. 2011 Jul 20;29(21): 2866-2874.
10. TS Mok, Yi-Long Wu, S Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, P Sunpaweravong, Baohui Han, B Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin-Ji Yang, B Chewaskulyong, Haiyi Jiang, E L Duffield, CL Watkins, AA Armour, Masahiro Fukuoka. Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. New Engl J Med. 2009; 361(10):947-957